title: [Advances in surgical techniques and results of radical cystectomies for bladder cancer. 106 patients].
abstract: OBJECTIVE
  Retrospective analysis of result of radical cystectomy at Cochin Hospital.
  
  
  METHODS
  We report the results of a 106 patients series treated by radical cystectomy for bladder carcinoma after a 5-year period follow-up.
  
  
  RESULTS
  The extent of the tumour invasion according to pathological analysis was: pT1 or less: 26%, pT2 and pT3a: 33%, pT3b and over: 41%. Morbidity rate was 19% with a 7.5% reintervention rate. Long term complication rate was 31%, concerning essentially ureteral stenosis. A local recurrence or distant metastasis occurred in 35% of patients. Local recurrence rate was 10.7%. Cancer specific survival rates were 88%, 81% and 42% for pT1, pT2-pT3a, and pT3b patients respectively.
  
  
  CONCLUSIONS
  The present results confirm that radical cystectomy is the most effective curative treatment for invasive bladder carcinoma.
authors.affiliation: Service d'urologie, Hôpital Cochin, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Zerbib
authors.forename: D
authors.initials: D
authors.lastname: Thirouard
authors.forename: S
authors.initials: S
authors.lastname: Conquy
authors.forename: N
authors.initials: N
authors.lastname: Thiounn
authors.forename: T
authors.initials: T
authors.lastname: Flam
authors.forename: B
authors.initials: B
authors.lastname: Debré
mesh_terms: D000328:Adult; D000368:Aged; D015653:Cystectomy / Q000009:adverse effects / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009017:Morbidity; D009364:Neoplasm Recurrence, Local / Q000209:etiology*; D009367:Neoplasm Staging; D018579:Patient Selection; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*
vernacular_title: Evolution des techniques chirurgicales et résultats des cystectomies à visée curative pour cancer de vessie. A propos de 106 patients.